Gen-Probe Incorporated, a developer of molecular diagnostic products and services, has received Health Canada approval for its Panther system.

The Panther system is an automated and integrated molecular testing system which is designed with the flexibility to handle a wide range of testing needs.

The system will be used to run the Gen-Probe’s dual test – Aptima Combo 2 assay to detect common sexually transmitted infections chlamydia and gonorrhea.

Gen-Probe is also developing other qualitative and quantitative assays for the Panther system.

Gen-Probe president and CEO Carl Hull said they believe the Panther system will revolutionize molecular diagnostics by offering customers high levels of productivity and instrument flexibility for clinical chemistry and immunoassay systems.

Gen-Probe has submitted an aplication to the US Food and Drug Administration to clear its Panther system.